news
Cancer immunotherapy drug discovery outsourcing size to increase globally
A report has shown that the immuno-oncology drug discovery outsourcing market is set to be worth $2563 million by 2030.
List view / Grid view
GenScript
article
Under the microscope: Keying into UK biosciences – GenScript Biotech operations lands in Oxford
With operations in over 100 countries worldwide, GenScript Biotech, an industry leader in biotechnology reagent services, has established a new UK office in the Oxford area to better connect with the UK biosciences sector.
article
Analysing proteomics data to translate in vivo studies as early as possible
Dr Antal Szalay, CEO and Founder of Ultimate Medicine, explores how the analysis of omics data, especially metabolomics and proteomics, can provide researchers with vital insight that can inform the development of drugs for conditions associated with age.
article
CRISPR-Cas9-based gene dropout screens: a powerful platform for drug discovery
CRISPR holds great promise in advancing pharmacological research and has fuelled the rapid expansion of using gene-edited cells for drug discovery processes. CRISPR-Cas9 dropout screens have emerged as a useful tool for high-throughput large-scale loss-of-function screens, which seek to identify the relationship between genotype and phenotype. Dr Pushpanathan Muthuirulan, Research…
article
The diversity of synthetic biology applications
Synthetic biology processes can be useful to therapeutic development, diagnostics and vaccine advancement. Drug Target Review’s Victoria Rees spoke with Dr Jim Collins, Termeer Professor of Medical Engineering & Science at MIT and Founding Core Faculty & Lead, Living Cellular Devices at the Wyss Institute at Harvard University, to explore…
article
The benefits of lab automation in life sciences
While researchers conduct their studies, constraints such as time can impact their work. Dr Ian Holland from the University of Edinburgh spoke with Drug Target Review’s Deputy Editor Victoria Rees to explain how lab automation can offer a solution to these challenges and enhance output for scientists.
article
The potential of epigenomic medicine in cardiology
Advances in genomic medicine are playing an increasingly important role in the field of cardiology. Better analysis and understanding of patient genomic and epigenomic information can enable more personalised patient treatment and medical intervention. Here, Professor John Giannios considers the potential to use genomic medicine to prevent, monitor, diagnose and…
article
The development of biomaterial-based vaccine platforms against viruses
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
article
Drug Target Review Vaccine Development ebook 2021
This ebook includes articles discussing why biomaterial and nanoparticle-based formulations could lead to the next generation of vaccines and exploring how a new rhinovirus vaccine showed promise in pre-clinical studies.
article
Broad T-cell responses: designing a rhinovirus vaccine
The multiple serotypes of rhinovirus have presented difficulties for vaccine developers. Now, a team led by Professor Gary McLean from London Metropolitan University and Imperial College London, alongside Professor Sebastian Johnston from Imperial, has formulated a potential vaccine. Nikki Withers spoke to McLean to discover how the vaccine works and…
whitepaper
Product hub: A cost, time and labour-saving protein purification platform
In February 2021, US biotech company GenScript launched an updated version of its semi-automated system, AmMag™ SA Plus.
article
Neoantigens: presenting new vaccine opportunities in immuno-oncology
Neoantigens have gained much interest in recent years, mainly due to their ability to elicit a strong, specific immune response. Nikki Withers spoke to two immunology experts to explore the progress being made and assess what remains challenging for cancer investigators working on these transformational therapies.
article
Expert view: GenScript’s unique four-tier platform for successful synthesis of challenging neoantigen peptides for precision medicine
Despite hundreds of off-the-shelf treatments, cancer remains the second leading cause of death globally.
article
Immuno-oncology In-Depth Focus 2020
This in-depth focus features articles on using combinations of immuno-oncology drugs to target solid tumours and haematological cancers and how neoantigens of cancer cells could be used as the basis of novel immuno-oncology vaccines.
article
Hitting the target – utilising recombinant antibodies for viral research
Having worked in antibody research for over 20 years, Gary McLean has seen how the industry has progressed and understands the potential that antibodies have in the future of medicine. Nikki Withers hears how the focus has shifted from discovery to genetic sequence manipulation and how this can be applied…